The challenge of HIV treatment in an era of polypharmacy
暂无分享,去创建一个
[1] C. Marzolini,et al. Polypharmacy and drug-drug interactions in HIV-infected subjects in the region of Madrid, Spain: a population-based study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] Samah J. Jarad,et al. Polypharmacy, hazardous alcohol and illicit substance use and serious falls among PLWH and uninfected comparators. , 2019, Journal of acquired immune deficiency syndromes.
[3] J. Parienti,et al. Cushing's syndrome due to interaction between ritonavir or cobicistat and corticosteroids: a case-control study in the French Pharmacovigilance Database. , 2019, The Journal of antimicrobial chemotherapy.
[4] A. Winston,et al. Risk factors and impact of patterns of co-occurring comorbidities in people living with HIV. , 2019, AIDS (London).
[5] E. M. Kalmar,et al. Getting older with HIV: increasing frequency of comorbidities and polypharmacy in Brazilian HIV patients. , 2019, AIDS research and human retroviruses.
[6] F. Palella,et al. Examination of Polypharmacy Trajectories Among HIV-Positive and HIV-Negative Men in an Ongoing Longitudinal Cohort from 2004 to 2016. , 2019, AIDS patient care and STDs.
[7] C. Marzolini,et al. Prescribing issues in elderly individuals living with HIV , 2019, Expert review of clinical pharmacology.
[8] C. Flexner,et al. Predicting Drug–Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling , 2019, The Journal of infectious diseases.
[9] Marco Siccardi,et al. A Comprehensive Framework for Physiologically‐Based Pharmacokinetic Modeling in Matlab , 2019, CPT: pharmacometrics & systems pharmacology.
[10] K. Anastos,et al. Non-HIV Comorbid Conditions and Polypharmacy Among People Living with HIV Age 65 or Older Compared with HIV-Negative Individuals Age 65 or Older in the United States: A Retrospective Claims-Based Analysis. , 2019, AIDS patient care and STDs.
[11] E. Gardner,et al. Risk and Cost Associated With Drug–Drug Interactions Among Aging HIV Patients Receiving Combined Antiretroviral Therapy in France , 2019, Open forum infectious diseases.
[12] J. Velez,et al. Non-AIDS-related comorbidities in people living with HIV-1 aged 50 years and older: The AGING POSITIVE study. , 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[13] A. Winston,et al. Polypharmacy and Drug–drug Interactions in Older and Younger People Living with HIV: The POPPY Study , 2019, Antiviral therapy.
[14] A. Winston,et al. Patterns of Co-occurring Comorbidities in People Living With HIV , 2018, Open forum infectious diseases.
[15] A. Mocroft,et al. Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort , 2018, AIDS.
[16] C. Katlama,et al. Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients , 2018, PloS one.
[17] E. Clementi,et al. Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice , 2018, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[18] Ju-Young Shin,et al. Assessment of Consistency of Drug Interaction Information in Drug Labels Among the United States, the United Kingdom, China, Japan, and Korea , 2018, Clinical pharmacology and therapeutics.
[19] M. Battegay,et al. Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes , 2018, Clinical Pharmacokinetics.
[20] P. Neuvonen,et al. Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel , 2018, Clinical pharmacology and therapeutics.
[21] B. Clotet,et al. Recurrent coronary disease in HIV‐infected patients: role of drug–drug interactions , 2018, British journal of clinical pharmacology.
[22] M. Núñez-Núñez,et al. Interacciones potenciales en una cohorte de pacientes VIH positivos de edad avanzada , 2018 .
[23] C. Kerr. 06 / SCREENING FOR SEXUAL HEALTH INFECTIONS INCLUDING CHLAMYDIA, GONORRHEA AND SYPHILIS IN ACCORDANCE WITH EUROPEAN AIDS CLINICAL SOCIETY (EACS) GUIDELINES , 2018 .
[24] A. Kahn,et al. Cancer Risk in Older Persons Living With Human Immunodeficiency Virus Infection in the United States , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] T. Naito,et al. Comorbidities and the use of comedications in people living with HIV on antiretroviral therapy in Japan: a cross-sectional study using a hospital claims database , 2018, BMJ Open.
[26] F. Stanaway,et al. Polypharmacy among HIV positive older adults on anti-retroviral therapy attending an urban clinic in Uganda , 2018, BMC Geriatrics.
[27] E. Sprinz,et al. Comorbidity is more common and occurs earlier in persons living with HIV than in HIV-uninfected matched controls, aged 50 years and older: A cross-sectional study. , 2018, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[28] M. Battegay,et al. Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications , 2018, Antimicrobial Agents and Chemotherapy.
[29] C. Mussi,et al. The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 – 74 years and more than 75 years , 2018, BMC Geriatrics.
[30] A. Taburet,et al. Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review , 2018, British journal of clinical pharmacology.
[31] A. Justice,et al. Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals , 2018, AIDS.
[32] A. Justice,et al. Non antiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals. , 2018, AIDS.
[33] D. Kuh,et al. Associations Between Polypharmacy and Cognitive and Physical Capability: A British Birth Cohort Study , 2018, Journal of the American Geriatrics Society.
[34] Y. Daali,et al. Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites , 2018, Clinical Pharmacokinetics.
[35] M. Shebley,et al. Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model , 2018, Journal of Pharmacokinetics and Pharmacodynamics.
[36] C. B. Hare,et al. A Pharmacist‐Led Program to Evaluate and Reduce Polypharmacy and Potentially Inappropriate Prescribing in Older HIV‐Positive Patients , 2017, Pharmacotherapy.
[37] A. d’Arminio Monforte,et al. Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study , 2017, PloS one.
[38] P. Reiss,et al. Higher Prevalence and Faster Progression of Chronic Kidney Disease in Human Immunodeficiency Virus–Infected Middle-Aged Individuals Compared With Human Immunodeficiency Virus–Uninfected Controls , 2017, The Journal of infectious diseases.
[39] J. George,et al. Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran , 2017, Antimicrobial Agents and Chemotherapy.
[40] L. Calza,et al. Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV‐1 infection , 2017, HIV medicine.
[41] W. Spreen,et al. Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects , 2017, Antimicrobial Agents and Chemotherapy.
[42] C. Katlama,et al. Ageing with HIV: do comorbidities and polymedication drive treatment optimization? , 2017, HIV medicine.
[43] C. Sabin,et al. Epidemiology of ageing with HIV: what can we learn from cohorts? , 2017, AIDS.
[44] J. Sterne,et al. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies , 2017, The lancet. HIV.
[45] P. Rochon,et al. The prescribing cascade revisited , 2017, The Lancet.
[46] K. Gough,et al. Extensive Bruising and Elevated Rivaroxaban Plasma Concentration in a Patient Receiving Cobicistat-Boosted Elvitegravir , 2017, The Annals of pharmacotherapy.
[47] S. Walmsley,et al. Increase in international normalized ratio after switching from atazanavir/ritonavir to darunavir/cobicistat in a patient on warfarin: boosters are not always equal. , 2017, AIDS.
[48] A. Pottegård,et al. Use of non-antiretroviral drugs among individuals with and without HIV-infection: a Danish nationwide study , 2017, Infectious diseases.
[49] M. Zwahlen,et al. Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population , 2016, AIDS.
[50] R. Krishna,et al. Effect of metal‐cation antacids on the pharmacokinetics of 1200 mg raltegravir , 2016, The Journal of pharmacy and pharmacology.
[51] L. Waters,et al. Iatrogenic Cushing's syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies. , 2016, Clinical medicine.
[52] M. Egger,et al. Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population , 2016, Current opinion in HIV and AIDS.
[53] S. Rannard,et al. Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy. , 2016, Advanced drug delivery reviews.
[54] B. Wynne,et al. The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects , 2016, Journal of acquired immune deficiency syndromes.
[55] C. Marzolini,et al. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. , 2016, The Journal of antimicrobial chemotherapy.
[56] L. Calza,et al. Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients. , 2016, The Journal of antimicrobial chemotherapy.
[57] B. KrentzHartmut,et al. The Impact of Non-Antiretroviral Polypharmacy on the Continuity of Antiretroviral Therapy (ART) Among HIV Patients , 2016 .
[58] D. Back,et al. Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[59] Mary Jordan Samuel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults , 2015, Journal of the American Geriatrics Society.
[60] Richard D Moore,et al. Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. , 2015, Annals of internal medicine.
[61] C. Corallo,et al. Postoperative Bleeding After Administration of a Single Dose of Rivaroxaban to a Patient Receiving Antiretroviral Therapy , 2015, Drug Safety - Case Reports.
[62] A. Mangoni,et al. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis. , 2015, British journal of clinical pharmacology.
[63] M. Preisig,et al. Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population , 2015, Open forum infectious diseases.
[64] T. Hallett,et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study , 2015, The Lancet. Infectious diseases.
[65] C. Fagard,et al. Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[66] P. Fulco,et al. An unexpected interaction between warfarin and cobicistat-boosted elvitegravir. , 2015, AIDS.
[67] Danijela Gnjidic,et al. Reducing inappropriate polypharmacy: the process of deprescribing. , 2015, JAMA internal medicine.
[68] G. Dolci,et al. Aging with HIV vs. HIV Seroconversion at Older Age: A Diverse Population with Distinct Comorbidity Profiles , 2015, PloS one.
[69] M. Budoff,et al. HIV Infection, Cardiovascular Disease Risk Factor Profile, and Risk for Acute Myocardial Infarction , 2015, Journal of acquired immune deficiency syndromes.
[70] S. Piscitelli,et al. Pharmacokinetics of Dolutegravir When Administered With Mineral Supplements in Healthy Adult Subjects , 2014, Journal of clinical pharmacology.
[71] P. Reiss,et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[72] M. Goldstein,et al. Health Outcomes Associated with Polypharmacy in Community‐Dwelling Older Adults: A Systematic Review , 2014, Journal of the American Geriatrics Society.
[73] Paul Gallagher,et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2 , 2014, Age and ageing.
[74] M. Winniford,et al. Impact of Clinical and Therapeutic Factors on Incident Cardiovascular and Cerebrovascular Events in a Population‐Based Cohort of HIV‐Infected and Non–HIV‐Infected Adults , 2014, Clinical cardiology.
[75] C. Boyd,et al. Patient-centered care for people living with multimorbidity. , 2014, Current opinion in HIV and AIDS.
[76] B. Feldt-Rasmussen,et al. Increased risk of dialysis and end-stage renal disease among HIV patients in Denmark compared with the background population. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[77] R. Ebrahimi,et al. Fanconi Syndrome Accompanied by Renal Function Decline with Tenofovir Disoproxil Fumarate: A Prospective, Case-Control Study of Predictors and Resolution in HIV-Infected Patients , 2014, PloS one.
[78] V. Valcour,et al. Polypharmacy, Drug–Drug Interactions, and Potentially Inappropriate Medications in Older Adults with Human Immunodeficiency Virus Infection , 2014, Journal of the American Geriatrics Society.
[79] M. Taljaard,et al. A cross-sectional, population-based study measuring comorbidity among people living with HIV in Ontario , 2014, BMC Public Health.
[80] M. Battegay,et al. Gastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virus. , 2014, Swiss medical weekly.
[81] James J. Goedert,et al. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada , 2013, PloS one.
[82] D. Nguyen,et al. Inhaled corticosteroid use in HIV‐positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management , 2013, HIV medicine.
[83] A. Mathias,et al. Pharmacokinetics of Once-Daily Boosted Elvitegravir When Administered in Combination With Acid-Reducing Agents , 2013, Journal of acquired immune deficiency syndromes.
[84] A. Forrest,et al. Pharmacokinetics of two common antiretroviral regimens in older HIV‐infected patients: a pilot study , 2013, HIV medicine.
[85] B. Gazzard,et al. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. , 2013, The Journal of antimicrobial chemotherapy.
[86] Benoit Chauvin,et al. Drug–Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors , 2013, Clinical Pharmacokinetics.
[87] J. Chmiel,et al. Polypharmacy and Risk of Antiretroviral Drug Interactions Among the Aging HIV-Infected Population , 2013, Journal of General Internal Medicine.
[88] M. Wiese,et al. Predicted metabolic drug clearance with increasing adult age. , 2013, British journal of clinical pharmacology.
[89] H. Crauwels,et al. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. , 2013, AIDS reviews.
[90] Richard D Moore,et al. Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection: A North American Cross Cohort Analysis , 2013, Journal of acquired immune deficiency syndromes.
[91] K. Dooley,et al. Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin: Results of a Phase 1 Study Among Healthy Subjects , 2013, Journal of acquired immune deficiency syndromes.
[92] Danijela Gnjidic,et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. , 2012, Journal of clinical epidemiology.
[93] J. Wooten. Pharmacotherapy Considerations in Elderly Adults , 2012, Southern medical journal.
[94] Emily R Hajjar,et al. Polypharmacy, adverse drug reactions, and geriatric syndromes. , 2012, Clinics in geriatric medicine.
[95] R. Weber,et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[96] R. Weber,et al. Ageing with HIV: medication use and risk for potential drug-drug interactions. , 2011, The Journal of antimicrobial chemotherapy.
[97] R. Bertz,et al. Effect of Low‐Dose Omeprazole (20 mg Daily) on the Pharmacokinetics of Multiple‐Dose Atazanavir With Ritonavir in Healthy Subjects , 2011, Journal of clinical pharmacology.
[98] R. Hamers,et al. Interaction between Antiretroviral Drugs and Acenocoumarol , 2011, Antiviral therapy.
[99] P. Anderson,et al. Effect of Antacids on the Pharmacokinetics of Raltegravir in Human Immunodeficiency Virus-Seronegative Volunteers , 2010, Antimicrobial Agents and Chemotherapy.
[100] M. Lederman,et al. Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. , 2010, AIDS research and human retroviruses.
[101] V. Sharp,et al. Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis. , 2009, The AIDS reader.
[102] P. Fulco,et al. Possible Antiretroviral Therapy‐Warfarin Drug Interaction , 2008, Pharmacotherapy.
[103] K. Markides,et al. Association of Suboptimal Prescribing and Change in Lower Extremity Physical Function over Time , 2008, Gerontology.
[104] V. Appay,et al. Immune activation and inflammation in HIV‐1 infection: causes and consequences , 2008, The Journal of pathology.
[105] Mridula Nair,et al. Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable , 2007, Expert opinion on drug safety.
[106] C. Hughes,et al. Interaction between lopinavir/ritonavir and warfarin , 2007, Canadian Medical Association Journal.
[107] C. Fichtenbaum,et al. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers , 2005, Clinical pharmacology and therapeutics.
[108] Stephen H. D. Jackson,et al. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. , 2003, British journal of clinical pharmacology.
[109] D. Singer,et al. Polypharmacy and medication adherence in patients with type 2 diabetes. , 2003, Diabetes care.
[110] A. Levy,et al. Effect of Number of Medications on Cardiovascular Therapy Adherence , 2002, The Annals of Pharmacotherapy.
[111] J. Avorn,et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. , 1997, American journal of hypertension.
[112] C. Flexner,et al. Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis , 2019, Current opinion in HIV and AIDS.
[113] M. Boffito,et al. Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[114] M. Núñez-Núñez,et al. Potential interactions in a cohort of elderly hiv-positive patients. , 2018, Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria.
[115] A. Mocroft,et al. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. , 2016, The lancet. HIV.
[116] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.